Validation data for Raji-hCTLA4 Cells

https://www.invivogen.com/raji-hctla4

For research use only

Version 19B04-NJ

Raji-hCTLA4 cells were developed from the Raji cell line to overexpress the human cytotoxic T cell lymphocyte antigen-4 (CTLA-4, also known as CD152) gene. Raji-hCTLA4 cells were designed as target cells in InvivoGen's antibody-dependent cellular cytotoxicity (ADCC) assay using clinically-relevant anti-human CTLA-4 monoclonal antibodies (mAbs). Human CTLA-4 expression by Raji-hCTLA4 cells has been verified by flow-cytometry, and induction of ADCC has been validated using InvivoGen's combinations of anti-human CTLA-4 antibody isotypes and Jurkat-NFAT Lucia™ CD16 reporter cell line. The level of ADCC induction is measured as a bioluminescent signal produced by an NFAT-dependent Lucia luciferase reporter protein. Antibodies displaying lower EC_{50} have higher ADCC potency.

ADCC assay using various anti-human CTLA-4 (Ipilimumab) antibody isotypes and Raji-hCTLA4 target cells



Comparison of ADCC potency for native and engineered anti-human CTLA-4 antibody isotypes: Raji-hCTLA4 cells were incubated with gradient concentrations of Anti-hCTLA4 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with targets cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com